Ovarian Sertoli-Leydig cell tumours (OSLCT) are rare and typically present with androgenic manifestations in women of the 2nd-3rd decade. Out of 228 diagnoses of ovarian sex cord-stromal tumours recorded at an academic institution during a 14-year period, eight women were surgically treated for OSLCT. Patient mean age was 54.8 years (range 19-81), five women being in the postmenopausal stage (62.5%). Only one woman presented with androgenic manifestations (12.5%), four with abnormal/postmenopausal uterine bleeding (50%), and three with abdominal pain (37.5%). Fertility sparing or radical surgery was performed depending on patient age and stage of disease. The only patient with an advanced disease (FIGO stage IV) was referred to palliative care postoperatively. The other seven were at FIGO stage I. Five of them were free from disease at a mean follow-up of 67 months, while the remaining two were lost at follow-up. The youngest woman of the series, treated with fertility-preserving unilateral salpingo-oophorectomy at the age of 19, had two spontaneous pregnancies and deliveries of healthy babies during a 10-year follow-up period. In conclusion, our single institution 14-year experience demonstrates that the diagnosis of OSLCT is particularly challenging since many patients are older than expected and lack androgenic manifestations. Impact statement • What is already known on this subjectOvarian Sertoli-Leydig cell tumours (OSLCT) are rare and are thought to typically present with androgenic manifestations in women of the 2nd-3rd decade. • What the results of this study addOur single institution 14-year experience shows that a high proportion of women with ovarian Sertoli-Leydig cell tumours may not present with androgenic manifestations, and many of them also are in the postmenopausal stage. Most patients have a good prognosis and fertility-preserving surgery in younger women can lead to spontaneous pregnancies and deliveries of healthy children after treatment. • What are the implications of these findings for clinical practice and/or further researchThe diagnosis of OSLCT is particularly challenging and therefore not reached before surgery in most of the cases. However, while hysterectomy with bilateral salpingo-oophorectomy and surgical staging are recommended for women with higher stage or no fertility wish, fertility-sparing surgery should be considered in younger women with early disease. Therefore, further research should focus on non-invasive diagnosis possibly by means of laboratory or imaging techniques.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/01443615.2017.1291590 | DOI Listing |
Alzheimers Dement
December 2024
Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Background: Accumulating evidence has shown the neuroprotective effects of estrogen on cognition function, for example delaying the cognitive deterioration in patients with Alzheimer's disease (AD). However, the clinical usage of estrogen in AD remains controversial. The cytochrome P450 aromatase encoded by CYP19A1, is a key enzyme catalyzing the C19 androgen conversion to C18 estrogen, which induces testosterone to estradiol and androstenedione to estrone.
View Article and Find Full Text PDFPharmacol Ther
December 2024
Institute of Microbiology and Molecular Genetics, University of the Punjab, New Campus, Lahore 54590, Pakistan. Electronic address:
Polycystic Ovarian Syndrome is one of the major prevalent causes of infertility reported worldwide nearly 6-26 %, especially in girls hitting puberty and women at their childbearing age. The main clinical manifestations include irregular menstrual cycle, small cysts on one or both ovaries, chronic oligo-anovulation, and hirsutism. The etiological criteria are very complex and related to many factors like obesity, insulin sensitivity, inflammation, hyperandrogenism, diabetes mellitus type II, cardiovascular diseases, and dysbiosis of gut microbiota.
View Article and Find Full Text PDFUrol Oncol
December 2024
Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria; Department of Physiology, College of Health Sciences, Crescent University, Abeokuta, Ogun State, Nigeria. Electronic address:
Several studies indicated that prostate cancer has a hereditary component. In particular, a significant risk of prostate cancer has been linked to a tight familial lineage. However, to provide insight into how prostate cancer is inherited, characterising its genetic profile is essential.
View Article and Find Full Text PDFMed Sci Monit
December 2024
Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Yunnan Provincial Dermatology Hospital, Kunming, Yunnan, China.
Acne vulgaris is a chronic inflammatory disease of the hair follicle-sebaceous gland unit and is the most common skin disorder worldwide. Although it can occur at any age, it predominantly affects young individuals, manifesting as comedones, papules, pustules, cysts, and nodules, primarily in the sebaceous-rich areas of the face, often in a symmetrical distribution. The development of acne vulgaris is believed to result from a combination of genetic and environmental factors, including sun exposure, skincare habits, diet, sleep patterns, and psychological stress, all of which can induce or exacerbate the condition.
View Article and Find Full Text PDFInt J Urol
December 2024
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Prostate cancer (PC) growth is hormone-dependent and it frequently develops distant metastases as disease progresses. Patients with metastatic castration-sensitive prostate cancer (mCSPC) initially respond to androgen deprivation therapy (ADT) but eventually become refractory and develop metastatic castration-resistant prostate cancer (mCRPC). Castration-resistance is associated with high lethality and metastases confer poor prognosis, therefore unmet needs in treatment for mCSPC remain high.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!